Format

Send to

Choose Destination
Diabetes Res Clin Pract. 2016 May;115:133-6. doi: 10.1016/j.diabres.2016.01.015. Epub 2016 Jan 16.

Successful switch from insulin to oral sulfonylurea therapy in HNF1A-MODY Tunisian patient with the P291fsinsC mutation.

Author information

1
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: souhaira24@yahoo.fr.
2
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: azzadendana@yahoo.fr.
3
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: ilhembarboura@yahoo.fr.
4
Endocrinology Unit, University Hospital of Monastir, Monastir 5000, Tunisia. Electronic address: ineskhoc@yahoo.fr.
5
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: hindachahed@yahoo.fr.
6
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: trimechesaly@yahoo.fr.
7
Biochemistry Laboratory, CHU Farhat Hached, Sousse 4000, Tunisia. Electronic address: MILED.A@rns.tn.

Abstract

The hot spot mutation P291fsinsC was identified for the first time in a 26 years old Tunisian woman. The low serum level of high C-reactive protein was helpful to target the HNF1A gene. Due to the molecular diagnosis, the change from insulin to sulfonylurea therapy was performed successfully.

KEYWORDS:

HNF1A-MODY; Molecular diagnosis; Monogenic diabetes; Sulfonylurea; hs-CRP

PMID:
26822262
DOI:
10.1016/j.diabres.2016.01.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center